LONA - Athira Pharma, Inc.

9.22
-0.160   -1.735%

Share volume: 34,974
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$9.38
-0.16
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 22%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.06%
1 Month
-1.60%
3 Months
50.16%
6 Months
134.61%
1 Year
3,327.51%
2 Year
341.15%
Key data
Stock price
$9.22
P/E Ratio 
0.00
DAY RANGE
$8.79 - $9.58
EPS 
-$3.04
52 WEEK RANGE
$0.23 - $14.21
52 WEEK CHANGE
$3,103.61
MARKET CAP 
16.328 M
YIELD 
N/A
SHARES OUTSTANDING 
3.944 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
2.96
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$42,683
AVERAGE 30 VOLUME 
$48,137
Company detail
CEO: Mark J. Litton
Region: US
Website: athira.com
Employees: 40
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in Phase 3 and ACT-AD clinical trials for the treatment of Alzheimer's disease.

Recent news